key: cord-0015825-lel5jl6p
authors: Song, Weilin; Chen, Andrew X.; Singh, Rishi P.; Rachitskaya, Aleksandra V.
title: Appointment Trends in New and Established Patients in Ophthalmology and Optometry at the Time of a Pandemic
date: 2021-03-02
journal: Can J Ophthalmol
DOI: 10.1016/j.jcjo.2021.02.003
sha: 2a6c723c92111a8b253d5e63561d3748c884d666
doc_id: 15825
cord_uid: lel5jl6p

nan

In response to COVID-19 being formally declared a pandemic, US health care systems implemented protocols aimed at mitigating risk for both patients and providers. 1 The American Academy of Ophthalmology and American Optometric Association recommended delaying all elective ambulatory provider visits and rescheduling routine ophthalmic visits. 2, 3 Although these measures reduced the potential for transmission, little is known about how outpatient ophthalmic care has been affected. The current study evaluated the effect of the COVID-19 lockdown on both new and established patients of different disease acuity scheduled to be seen in optometry, general, and subspecialty clinics.

A retrospective chart review was performed of all scheduled appointments of adult patients from March 14 through May 4, 2020 (COVID-19 period) . A comparable standard operations time was chosen for comparison. Only the first scheduled visit during this period was used so that each visit was associated with 1 unique patient. All patients were stratified by provider subspecialty. To assess the acuity of the disease, established patients were stratified by duration of time between the last visit before the COVID-19 period and the COVID-19 scheduled visit ( with commercial insurance (completed: 30% versus not: 25%; p < 0.0001) were more likely to complete the scheduled appointment (Table 1 ). Of 28 383 established patients, those who required more frequent follow-up (Group 1: 63%, Group 2: 69%) had fewer cancellations than patients with lower acuity of disease (Group 3: 78%, Group 4: 84%; p < 0.0001) ( Table 2) . However, the time between the intended follow-up and actual follow-up more than tripled in higher acuity patients (Group 1: from 3.37 to 13.51 weeks; Group 2: from 8.02 to 18.14 weeks; Group 3: from 16.47 to 27.42 weeks; Group 4: from 59.73 to 67.71 weeks). Of the cancelled appointments, 69% and 66% rescheduled the missed appointment in Groups 1 and 2, respectively, which was higher than in patients who had lower acuity of disease (Group 3: 63%, Group 4: 60%; p < 0.0001).

When analyzed by subspecialty, the highest percentage of completed appointments among all scheduled patients was seen in retina/uveitis (1652 [ This study describes the profound effects of the COVID-19 lockdown within a multispecialty ophthalmology and optometry practice. The access to care was affected for both new and established patients. Although patients with more acute conditions were seen more frequently and had higher rescheduling rates, the follow-up time was triple that intended. The discrepancy seen between subspecialties is multifactorial and deserves further analysis on multiinstitutional level. Although the findings may not be generalizable to all settings, they provide a unique analysis of how a pandemic affects outpatient clinical care, which is the first step in implementing changes that minimize interruptions in care and prepare for transitions back toward a standard practice. 4

Supplementary material associated with this article can be found in the online version at doi:10.1016/j. jcjo.2021.02.003.

X XD 1 X XWeilin Song,D 2 X X* D 3 X XAndrew X. Chen,D 4 X X y,z D 5 X XRishi P. Singh,D 6 X X z D 7 X XAleksandra V. RachitskayaD 8 X X § 

Ophthalmology practice during the COVID-19 pandemic

HPI CoronaVirus Statement 1-30-20.pdf. American Optometric Association

Ophthalmology after coronavirus disease 2019 (COVID-19): transition back to patient care

Footnotes and Disclosure The authors have made the following disclosures: W.S.: RPB Medical Student Eye Research Fellowship (grant)

C: NIH Institutional Training T32 Award (grant) and RPB Medical Student Eye Research Fellowship (grant)

Alcon, Novartis, Zeiss, Allergan (all personal fees)

Graybug (grant), Zeiss (personal fees)

Correspondence to: Aleksandra V. Rachitskaya, MD: rachita@ccf.org.